
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses On Their Investment In Atyr Pharma, Inc. Of Class Action Lawsuit And Upcoming Deadlines - ATYR
The class action concerns whether aTyr and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until December 8, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired aTyr securities during the Class Period. A copy of the Complaint can be obtained a t .
[Click here for information about joining the class action]On September 15, 2025, aTyr hosted an investor call announcing that the EFZO-FIT study-a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous Efzofitimod in patients with pulmonary sarcoidosis-did not meet its primary endpoint in change from baseline in mean daily OSC dose at week 48. Additionally, aTyr announced that the Company's next step was to engage with the U.S. Food and Drug Administration to determine a path forward, given the disappointing topline results.
On this news, aTyr's stock price fell $5.01 per share, or 83.17%, to close at $1.01 per share on September 15, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See .
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
...
646-581-9980 ext. 7980

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Thinkmarkets Adds Synthetic Indices To Its Product Offering
- Ethereum Startup Agoralend Opens Fresh Fundraise After Oversubscribed $300,000 Round.
- KOR Closes Series B Funding To Accelerate Global Growth
- Wise Wolves Corporation Launches Unified Brand To Power The Next Era Of Cross-Border Finance
- Lombard And Story Partner To Revolutionize Creator Economy Via Bitcoin-Backed Infrastructure
- FBS AI Assistant Helps Traders Skip Market Noise And Focus On Strategy
Comments
No comment